Loading…
No business profile yet.
Size TRex Bio (TRXB) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $364M, the 2943rd largest of 3,117 United States companies the cockpit tracks. Shares closed at $13.26 on 6 Nov 2026.
Growth Revenue fell 100.0% over the last twelve months (peer median +2.3%).
Short interest Short interest is 0.7% of the free float (15 Oct 2026).
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | n/a | $0 | $39.1M |
| Revenue growth | — | -100% | — |
| Gross profit | n/a | -$1.54M | $36.6M |
| EBITDA | n/a | -$36.3M | $145,000 |
| Net income | n/a | -$34.8M | -$3.14M |
| Free cash flow | n/a | -$41.4M | -$25.6M |
| Capital expenditure | n/a | $68,000 | $68,000 |
| Total debt | n/a | $717,000 | $696,000 |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | TRXB | Peer median | Rank in peer set |
|---|---|---|---|
| Distance from 52-week high | -19.9% | -38.2% | 2nd highest of 21 |
| Revenue growth (TTM) | -100.0% | +2.3% | lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| TRex Bio TRXB | United States | $364M | n/a | -100% | n/a | n/a | n/a | n/a |
| KYORIN Pharmaceutical 4569.T | Japan | $362M | -30% | -5% | 2% | 0.5× | 10.5% | +4.2% |
| Hinova Pharmaceuticals 688302.SS | China | $366M | -24% | +251% | -195% | 22.0× | n/a | n/a |
| Kingchem (Liaoning) Life Science 301509.SZ | China | $368M | -25% | +3% | 6% | 1.8× | 13.2% | +6.5% |
| Shukra Pharmaceuticals SHUKRAPHAR.NS | India | $372M | n/a | +115% | 57% | 46.9× | n/a | n/a |
| Avalo Therapeutics AVTX | United States | $372M | -68% | -87% | -154,844% | n/a | n/a | n/a |
| Lumosa Therapeutics 6535.TWO | Taiwan | $356M | -49% | -8% | -883% | 324.5× | n/a | n/a |
| Anhui Fengyuan Pharmaceutical 000153.SZ | China | $372M | -17% | -24% | 3% | 1.1× | 4.2% | +3.1% |
| Chongqing Hifuture Information Technology 002168.SZ | China | $372M | -23% | +2% | -6% | 8.3× | 16.3% | -14.0% |
| Unichem Laboratories UNICHEMLAB.NS | India | $373M | +28% | +9% | 5% | 1.5× | n/a | n/a |
| Rezolute RZLT | United States | $375M | +21% | n/a | n/a | n/a | n/a | n/a |
| Guizhou Yibai Pharmaceutical 600594.SS | China | $376M | -21% | -26% | -15% | 2.0× | 9.0% | -11.3% |
| Pharmicell 005690.KS | South Korea | $352M | -56% | +51% | 32% | 3.2× | -6.6% | +24.8% |
| Zhejiang East Asia Pharmaceutical 605177.SS | China | $348M | -3% | +3% | -17% | 3.1× | n/a | n/a |
| Opus Genetics IRD | United States | $348M | -19% | -36% | -513% | 29.9× | n/a | n/a |
| JCR Pharmaceuticals 4552.T | Japan | $383M | -11% | +3% | -14% | 2.9× | n/a | n/a |
| Atea Pharmaceuticals AVIR | United States | $346M | -21% | n/a | n/a | n/a | n/a | n/a |
| MapLight Therapeutics MPLT | United States | $385M | -75% | n/a | n/a | n/a | n/a | n/a |
| iX Biopharma 42C.SI | Singapore | $386M | +10% | -12% | -140% | 70.7× | n/a | n/a |
| Foresee Pharmaceuticals 6576.TWO | Taiwan | $343M | -9% | +6% | -104% | 22.9× | n/a | n/a |
| BioDlink International 1875.HK | Hong Kong | $342M | -29% | -51% | -31% | 4.9× | n/a | n/a |